Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder
Status:
Withdrawn
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the
growth of abnormal cells, either by killing the cells or by stopping them from dividing.
Giving low-doses of cytarabine may be an effective treatment for Down syndrome and transient
myeloproliferative disorder. Sometimes the disease may not need treatment until it
progresses. In this case, observation may be sufficient.
PURPOSE: This phase III trial is studying low-dose cytarabine to see how well it works in
treating infants with Down syndrome and transient myeloproliferative disorder.